<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00045968</url>
  </required_header>
  <id_info>
    <org_study_id>020221</org_study_id>
    <nct_id>NCT00045968</nct_id>
  </id_info>
  <brief_title>Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer</brief_title>
  <acronym>GBM</acronym>
  <official_title>A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwest Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwest Biotherapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to determine the efficacy of an investigational therapy
      called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated.
      Patients must enter screening at a participating site prior to surgical resection of the
      tumor. Patients will receive the standard of care, including radiation and Temodar therapy
      and two out of three will additionally receive DCVax-L, with the remaining one third
      receiving a placebo. Patients randomized to the placebo arm will have the option to receive
      DCVax-L in a crossover arm upon documented disease progression. (note: DCVax-L when used for
      patients with brain cancer is sometimes also referred to as DCVax-Brain)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase III trial is designed to evaluate the impact on disease progression and survival
      time, as well as safety, in patients following treatment with DCVax(R)-L, an immunotherapy
      treatment for GBM. The experimental therapy uses a patient's own tumor lysate and white
      blood cells from which precursors of the dendritic cells are isolated. The dendritic cell is
      the starter engine of the immune system.  The white cells are then made into dendritic cells
      and they are educated to &quot;teach&quot; the immune system how to recognize brain cancer cells.
      Eligible patients will receive a series of injections of DCVax-L, to activate and then boost
      the immune response to the tumor cells.

      The primary study endpoint is PFS (progression free survival), and the first secondary
      endpoint is overall survival (OS). Other endpoints include performance status, immune
      response, and also safety. Interim analyses to assess efficacy are incorporated in the trial
      design.

      Side effects reported from early trials are mostly mild, and may include skin reactions of
      redness, pain &amp; swelling at the injection site.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary objective of this study is to compare progression free survival from time of randomization between patients treated with DCVax-L and control patients.</measure>
    <time_frame>Time to tumor progression or death</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective is to compare overall survival and time to disease progression between DCVax-L treated and control patients.</measure>
    <time_frame>Until Death</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Glioblastoma</condition>
  <condition>GBM</condition>
  <condition>Grade IV Astrocytoma</condition>
  <condition>Glioma</condition>
  <condition>Brain Cancer</condition>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>treatment cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Chohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Autologous PBMC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dendritic cell immunotherapy</intervention_name>
    <description>Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment.  Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.</description>
    <arm_group_label>treatment cohort</arm_group_label>
    <arm_group_label>Placebo Chohort</arm_group_label>
    <other_name>DCVax-L</other_name>
    <other_name>DCVax</other_name>
    <other_name>DCVax-Brain</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients must meet the following inclusion criteria. All tests and eligibility
        criteria must be completed within four weeks of completion of radiation and chemotherapy,
        following surgery.

          -  Patients must have sufficient tumor lysate protein that was generated from the
             surgically obtained tumor material. Patients must also have sufficient DCVax-L
             product available after manufacturing. These determinations will be made by Cognate
             BioServices, Inc. (Cognate) and communicated to the clinical site through the
             Sponsor, or its designee.

          -  Patients with newly diagnosed, unilateral GBM (Grade IV) are eligible for this
             protocol. An independent neuropathologist will review this diagnosis during the
             enrollment process.

          -  Subjects ≥18 and ≤70 years of age at surgery who are capable of informed consent.
             Patients must be able to understand and sign the informed consent documents
             indicating that they are aware of the investigational nature of this study.

          -  Patients must have a life expectancy of &gt;8 weeks.

          -  Patients must have a KPS rating of ≥70 at the baseline visit (Visit 3).

          -  Primary therapy must consist of surgical resection with the intent for a gross or
             near total resection of the contrast-enhancing tumor mass, followed by conventional
             external beam radiation therapy and concurrent Temodar chemotherapy. Patients having
             a biopsy only will be excluded. These primary treatments must be completed at least
             two weeks prior to first immunization.

          -  Patients may have received steroid therapy as part of their primary treatment.
             Steroid treatment must be stopped at least 10 days prior to leukapheresis.

          -  Patients must not have progressive disease at completion of radiation therapy.
             Patients with suspected pseudoprogression will be enrolled and analyzed separately.

          -  Patients must be willing to forego cytotoxic anti-tumor therapies except temozolomide
             essentially according to the schedule of the Stupp Protocol (Stupp et al. N Engl J
             Med 352: 987-96, 2005) while being treated with DCVax-L. DCVax-L treatment must be
             given as described and temozolomide/Temodar treatment schedules must be given
             essentially according to the Stupp Protocol.

          -  Patients must have adequate bone marrow function (e.g., hemoglobin &gt;10 g/dl, white
             blood count 3600-11,000mm3, absolute granulocyte count ≥1,500/mm3, absolute
             lymphocyte count ≥1,000/mm3, and platelet count ≥100K/mm3. Eligibility level of
             hemoglobin can be reached by transfusion.

          -  Adequate liver function (SGPT, SGOT, and alkaline phosphatase ≤1.5 times upper limits
             of normals (ULN) and total bilirubin ≤1.5mg/dl), and adequate renal function (BUN or
             creatinine ≤1.5 times ULN) prior to starting therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Liau, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marnix L. Bosch, MBA, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Northwest Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marnix L Bosch, MBA, PhD</last_name>
    <phone>240-497-9022</phone>
    <email>marnix@nwbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shana Fetters</last_name>
      <phone>501-686-8274</phone>
      <email>FettersShanaM@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Shirley Ong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter East Bay Neuroscience Institute-Eden Medical Center</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorna Beccaria, RN</last_name>
      <phone>510-727-8267</phone>
      <email>BeccarL@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Tyler Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Ching</last_name>
      <phone>866-235-3031</phone>
      <email>AChing@coh.org</email>
    </contact>
    <investigator>
      <last_name>Jana Portnow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Siwak</last_name>
      <phone>714-456-8549</phone>
      <email>csiwak@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Daniela Bota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>93093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Brown</last_name>
      <phone>858-822-5377</phone>
      <email>bdbrown@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Santosh Kesari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Billingslea-Yoon, R.N.</last_name>
      <phone>310-267-2621</phone>
      <email>ebillingslea@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Liau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Ellis</last_name>
      <phone>949-764-5543</phone>
      <email>robin.ellis@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Duma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital of Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Holman</last_name>
      <phone>714-734-6200</phone>
      <phone_ext>40842</phone_ext>
      <email>Andrew.Holman@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>William Loudon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Institute for Medical Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Marlen, CCRC</last_name>
      <phone>916-453-5742</phone>
      <email>MarlenN@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Nora Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Pasadena Cancer Center</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Kilpatrick, RN</last_name>
      <phone>626-256-4673</phone>
      <email>Jkilpatrick@coh.org</email>
    </contact>
    <investigator>
      <last_name>Jana Portnow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Robischon</last_name>
      <phone>720-848-0661</phone>
      <email>Monica.robischon@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Lillehei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai CCOP</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leandro Pisano</last_name>
      <phone>305-674-2625</phone>
      <phone_ext>55629</phone_ext>
      <email>Leandro.pisano@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Jose Lutzky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Yoder, PharmD</last_name>
      <phone>312-996-9240</phone>
      <email>hyoder@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert Engelhard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne Sixta, RN, BSN, OCN</last_name>
      <phone>312-942-2388</phone>
      <email>Jeanne_Sixta@Rush.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Aiken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Margis</last_name>
      <phone>309-243-3621</phone>
      <email>cmargis@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Francois Geoffroy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IU Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Funke</last_name>
      <phone>317-278-0328</phone>
      <email>jmfunke@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KU Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Shores</last_name>
      <phone>913-588-1897</phone>
      <email>ashores@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Taylor, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Jensen</last_name>
      <phone>617-636-2694</phone>
      <email>jjensen@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Lynne Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Department of Neurosurgery</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Frisch</last_name>
      <phone>734-232-4843</phone>
      <email>kfrisch@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Blake Swihart</last_name>
      <phone>734-763-9705</phone>
      <email>blakeswi@umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Heth, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Leon, RN</last_name>
      <phone>313-916-6781</phone>
      <email>sleon9@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Tom Mikkelsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Nasseff Neuroscience Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilanjana Banerji</last_name>
      <phone>612-262-4837</phone>
      <phone_ext>na.Baner</phone_ext>
      <email>Nilanjana.Banerji@allina.com</email>
    </contact>
    <investigator>
      <last_name>John Trusheim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer McIntire, RN</last_name>
      <phone>816-932-7985</phone>
      <email>jmcintire@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Darren Lovick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Gwinn</last_name>
      <phone>314-747-4678</phone>
      <email>AGWINN@DOM.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>David Tran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Cappello</last_name>
      <phone>201-996-5098</phone>
      <email>LCappello@HackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Samuel Goldlust, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Eagan, RN</last_name>
      <phone>908-522-5843</phone>
      <email>pat.eagan@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael L Gruber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntington Hospital</name>
      <address>
        <city>Huntington</city>
        <state>New York</state>
        <zip>11743</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Prabhu, MA, CCRC</last_name>
      <phone>516-478-0010</phone>
      <email>kprabhu@nspc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Island Brain Tumor Centre at Neurological Surgery P.C.</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Prabhu, MA, CCRP</last_name>
      <phone>631-864-3900</phone>
      <email>kprabhu@nspc.com</email>
    </contact>
    <investigator>
      <last_name>Jai Grewal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Prabhu, MA, CCRP</last_name>
      <phone>516-478-0010</phone>
      <email>kprabhu@nspc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberky Prabhu</last_name>
      <phone>516-478-0010</phone>
      <email>kprabhu@nspc.com</email>
    </contact>
    <investigator>
      <last_name>Jai Grewal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Corpuz</last_name>
      <phone>212-342-2959</phone>
      <email>cc2638@columbia.edu</email>
    </contact>
    <contact_backup>
      <phone>212-305-9858</phone>
    </contact_backup>
    <investigator>
      <last_name>Fabio Iwamoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Nassau Community Hospital</name>
      <address>
        <city>Oceanside</city>
        <state>New York</state>
        <zip>11572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Prabhu, MA, CCRC</last_name>
      <phone>516-478-0010</phone>
      <email>kprabhu@nspc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Behr</last_name>
      <phone>585-276-3581</phone>
      <email>Jacqueline_Behr@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11571-9024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Prabhu, MA, CCRC</last_name>
      <phone>516-478-0010</phone>
      <email>kprabhu@nspc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Fiore, M.S.</last_name>
      <phone>631-444-9425</phone>
      <email>susan.fiore@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Raphael Davis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain and Spine Surgeons of New York and Northern Westchester Hospital</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Strack, RN</last_name>
      <phone>914-517-7982</phone>
      <email>jstrack@bssny.com</email>
    </contact>
    <investigator>
      <last_name>John Abrahams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Lynch</last_name>
      <phone>919-843-7112</phone>
      <email>becky_lynch@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Ewend, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Sifri, RN, BSN</last_name>
      <phone>513-584-0618</phone>
      <email>sifrisc@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Rekha Chaudhary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Naska</last_name>
      <phone>216-444-8923</phone>
      <email>naskat@ccf.org</email>
    </contact>
    <investigator>
      <last_name>David Peereboom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Krzemien, RN</last_name>
      <phone>216-983-3021</phone>
      <email>Henry.krzemien@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Andrew E. Sloan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Whitmire</last_name>
      <phone>570-214-9603</phone>
      <email>awhitmire@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Toms, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Wakefield</last_name>
      <phone>215-503-9110</phone>
      <email>meghan.wakefield@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Lyndon Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Bakalarski</last_name>
      <phone>401-444-9896</phone>
      <email>pbakalarski@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Heinrich Elinzano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Hospitals and Clinics</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele DeCandio</last_name>
      <phone>843-792-9016</phone>
      <email>decandio@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Pierre Giglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Thomas Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Grimes, RN</last_name>
      <phone>615-222-4356</phone>
      <email>ngrimes@sth.org</email>
    </contact>
    <investigator>
      <last_name>Steve Abram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katy Lyons, RN BSN CCRC</last_name>
      <phone>800-811-8480</phone>
      <email>katie.lyons@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Reid Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Clark</last_name>
      <phone>214-820-6168</phone>
      <email>Valerie.clark@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Karen Fink, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yvonne Kew, MD, PhD, Neuro-Oncology Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sun, MD, PhD</last_name>
      <phone>713-534-1300</phone>
      <email>sun.davidwei@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yvonne Kew, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimbra Harris</last_name>
      <phone>713-441-3834</phone>
      <email>ksharris@tmhs.org</email>
    </contact>
    <investigator>
      <last_name>Pamela New, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research at University of Texas Health Science Center San Antonio ( UTHSCA)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherie Noles</last_name>
      <phone>210-450-5964</phone>
      <email>nolesc@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Brenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research at University of Texas Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherie Noles</last_name>
      <phone>210-450-5964</phone>
      <email>nolesc@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Brenner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital Neuroscience Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Hansen</last_name>
      <phone>206-320-3542</phone>
      <email>Nathan.Hansen@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Charles Cobbs, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gal Maier</last_name>
      <phone>+44 (0) 203 299 7150</phone>
      <email>gal.maier@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Keyoumars Ashkan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.nwbio.com</url>
    <description>Northwest Biotherapeutics, Inc.</description>
  </link>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 11, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2002</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oncology</keyword>
  <keyword>neurology</keyword>
  <keyword>glioma</keyword>
  <keyword>brain tumor</keyword>
  <keyword>brain cancer</keyword>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>newly diagnosed glioblastoma</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>dendritic cells</keyword>
  <keyword>immune therapy</keyword>
  <keyword>GBM</keyword>
  <keyword>Brain cancer, primary</keyword>
  <keyword>tumor vaccine</keyword>
  <keyword>grade IV astrocytoma</keyword>
  <keyword>DCVax</keyword>
  <keyword>Grade IV brain cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
